Table 5. Results from cost-effectiveness and cost-utility analyses based on 1000 bootstrap replications.

Analysis type	Group (N)			Probability of highest net monetary benefit (WTP = 0),%			Probability of highest net monetary benefit (WTP = 18,000),%			Probability of highest net monetary benefit (WTP = 80,000),%
	Video	Text	Control	Video	Text	Control	Video	Text	Control	Video	Text	Control
Primary analysis
Prolonged abstinence (PA) a	670	708	721	42	16	42	70	11	20	90	7	3
QALY (EQ-5D-3L) b	667	704	717	38	18	45	39	18	43	41	20	39
Sensitivity analysis
Seven-day point prevalence abstinence (PPA) c	670	708	721	38	17	46	46	22	31	48	34	18
PA without surgery costs	670	708	721	41	17	42	68	12	20	90	7	3
PA without respondent costs	670	708	721	43	20	38	68	14	17	90	7	3
PA without medication costs	670	708	721	36	23	42	61	19	21	87	10	4
QALY without surgery costs	667	704	717	43	15	41	44	16	41	44	17	39
QALY without respondents costs	667	704	717	41	18	41	43	18	39	45	18	37
QALY without medication costs	667	704	717	35	27	38	38	26	37	40	24	36

^aCoded as 2 =  prolonged abstinent and 1 =  not prolonged abstinent,

^bbased on the Dutch algorithm for the EQ-5D-3L scores,

^ccoded as 2 =  seven-day point prevalence abstinent and 1 =  not seven-day point prevalence abstinent;